Stay updated with breaking news from Aaron Lisberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors Datopotamab...
The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.
Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.
Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan demonstrated a statistically significant improvement for the primary endpoint of...